Overview

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Status:
Completed
Trial end date:
2021-03-03
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics (PK), tolerability, and safety of brexpiprazole QW formulation administered as single and multiple doses in patients with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Brexpiprazole